Gilead Balances Trodelvy Setback With Once Weekly HIV Progress

• Gilead Sciences (NasdaqGS:GILD) discontinued the Phase 3 KEYNOTE-D46/EVOKE-03 trial of Trodelvy plus KEYTRUDA in first-line metastatic non-small cell lung cancer after the regimen did not show sufficient clinical benefit over standard-of-care.
• The company reported positive Phase 3 results from the ISLEND trials for a once-weekly oral HIV regimen combining islatravir and lenacapavir (ISL/LEN).
• These updates affect expectations for Trodelvy's potential label expansion in oncology and highlight a new direction for Gilead's HIV franchise.

Gilead Sciences, traded as NasdaqGS:GILD, has long been associated with antiviral therapies, especially in HIV and hepatitis, while also investing heavily in oncology. The mixed update on Trodelvy in metastatic non-small cell lung cancer and the once-weekly ISL/LEN HIV regimen gives you a clear view of how the company is balancing its cancer ambitions with its established HIV focus. For investors tracking drug pipelines, both announcements are central to how Gilead allocates capital and research effort across its core businesses.

The Trodelvy trial discontinuation may prompt closer scrutiny of Gilead's broader oncology plans, while the ISL/LEN data may draw attention to how a weekly oral option could fit within future HIV treatment patterns. Together, these events frame a period in which regulatory discussions, additional clinical data, and competitive responses could influence how the market views Gilead's pipeline mix.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

📰 Beyond the headline: 1 risk and 5 things going right for Gilead Sciences that every investor should see.

Quick Assessment

• ✅ Price vs Analyst Target: At US$128.10, the stock trades about 18.8% below the US$157.83 analyst target.
• ✅ Simply Wall St Valuation: Shares are flagged as trading 53.1% below an internal fair value estimate.
• ❌ Recent Momentum: The stock is down 2.5% over the last 30 days.

There's only one way to know the right time to buy, sell or hold Gilead Sciences. Head to Simply Wall St's company report for the latest analysis of Gilead Sciences's Fair Value.

Key Considerations

• 📊 The Trodelvy lung cancer setback reduces one potential oncology driver, while ISL/LEN supports the HIV franchise that many investors already focus on.
• 📊 Watch updates on Trodelvy in other cancer settings, timelines for ISL/LEN regulatory filings, and how the P/E of 17.26 compares to the 16.43 industry average.
• ⚠️ Simply Wall St flags high debt as a risk, which matters if pipeline disappointments limit future cash flow from new oncology products.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Gilead Sciences analysis. Alternatively, you can check out the community page for Gilead Sciences to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com